PSMA/NKG2DL/FAP-targeted Hi-TCR-T cells

N/A

Report date: 2026/01/16 20:01:23

Base Information

Drug NamePSMA/NKG2DL/FAP-targeted Hi-TCR-T cells
Drug Alias NameIL-7/IL-15/CCL21/PD-1 checkpoint-inhibitor/TGF1 inhibitor secreting anti-PSMA/NKG2DL/FAP TCR T-cell therapy (Hi-TCR-T cells) (Shenzhen Misheng Biotechnology/Seventh Affiliated Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionInterleukin-7 receptors stimulantsNKG2D ligands modulatorsC-C motif chemokine 21 stimulants +[8] 
TargetsProstate-Specific Membrane AntigenC-C motif chemokine 21NKG2D ligands +[8] 
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Misheng Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Misheng Biotechnology Co LtdSun Yat-Sen UniversityThe Seventh Affiliated Hospital Sun Yat-sen University
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A